Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UCB Holdings, Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners, meaning each examiner is handling a separate matter. Furthermore, the actions are located in 2 distinct art units, indicating that the company's pharmaceutical interests span different technical classifications. This distribution requires the applicant to monitor different examination styles simultaneously while maintaining a consistent overall strategy for the portfolio.
MIKNIS, ZACHARY J is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. The other pending action is handled by the other distinct examiner. This distribution across multiple art units and examiners suggests that the applicant must manage separate prosecution tracks, each potentially subject to different examiner preferences and art unit norms. Practitioners should be prepared to address the specific concerns of separate officials, even though the technical focus remains within the biotechnology field. The presence of 2 distinct art units indicates that the company's applications are classified under different categories, each with its own set of prior art.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605495 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | BEANE, RANDALL L | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605495 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | BEANE, RANDALL L | 43d overdue |
| 18599164 | MODULATORS OF COMPLEMENT ACTIVITY | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18599164 | MODULATORS OF COMPLEMENT ACTIVITY | MIKNIS, ZACHARY J | 1658 | §112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 17605495 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | BEANE, RANDALL L | 1654 | §103§112 | Final Rejection | 43d overdue | Pending | Oct 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUCB Holdings, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zachary J Miknis has the most, with 1 of UCB Holdings, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
